ClinicalTrials.gg
Not yet recruitingNCT06992999Updated May 12, 2026

Psilocybin for Treatment of OCD-2

A Phase 1/2 interventional study of Low Dose Psilocybin and High Dose Psilocybin in Obsessive - Compulsive Disorder, sponsored by Francisco A Moreno. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Francisco A Moreno · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 299 studies in Obsessive-Compulsive Disorder with a site in United States — 59 open to participants now, 77 under way, 2 of them phase 3. Obsessive-Compulsive Disorder · United States.

Planned enrollment
172nd of 246
20 · median 40
Started
2026
with 12 others
Phase 1/2
13 of 299
4 open now
Primary completion
2028-12
later than 54 of 76 live
Registered
283rd of 299
by date

Among the 299 studies in Obsessive-Compulsive Disorder with a site in United States, this one is the 172nd largest by planned enrollment of the 246 interventional ones that give a count, is one of 13 that started in 2026, is one of 13 in phase 1/2, reaches primary completion later than 54 of the 76 other live ones, and was the 283rd registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

59 of the 299 studies in Obsessive-Compulsive Disorder with a site in United States are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 299 studies in Obsessive-Compulsive Disorder with a site in United States, or all of them as a file.
02

Study summary

Previous research indicates that psilocybin, a drug that changes activity in brain areas believed to be involved in obsessive-compulsive disorder (OCD), might improve treatment for, and improve lives of, people diagnosed with OCD. The investigators propose to study 20 patients with symptomatic OCD who are not taking mind altering medications or street drugs, to participate in a 12 week study. Participants will be assigned (by luck of the draw) to take low or high dose psilocybin in four dosing sessions separated by 3 weeks. Measurements for the severity of OCD, ability to function, perception of quality of life, safety and tolerability will be measured at baseline prior to drug administration, during the dosing periods, and at the end of study. Other measurements will include brain imaging via fMRI and brain tracing via electroencephalogram (EEG). The investigators believe that during medically supervised dosing sessions, both doses of psilocybin will be safe and well tolerated, and will reduce OCD symptoms. Because psilocybin is a potent drug and especially at the higher dose may induce altered states of consciousness, a thoughtfully implemented procedure for participant safety is in place. Information will be obtained to explore the effects of altered states of consciousness in the outcome of treatment and to find the mechanism of benefit.

Read the detailed description

Obsessive-Compulsive Disorder (OCD) affects millions of Americans at some point during their lifetime, representing a great deal of individual suffering, social, and fiscal cost. Despite this, currently available medications fail to help as many as 40% of OCD patients, and those who respond to treatment often experience troublesome residual symptoms 4. Psilocybin holds promise as a novel approach in the treatment of OCD, supported by preliminary evidence that it achieves response and remission rates exceeding conventional interventions .

The broad long-term objectives of this research are to improve our available treatment options for OCD and advance the specific knowledge of neural mechanism explaining treatment response. Building on the investigative team's decades long work with synthetic psilocybin, data obtained during this proposed early phase clinical study may help improve the life of people affected with OCD and minimize society's burden.

The investigators propose a randomized, controlled trial of four sessions of psilocybin assigned to either low dose (10mg) or high dose (30 mg) in double masked fashion to 20 (10 per group) symptomatic and medication-free OCD patients. The study will evaluate the tolerability, safety, subjective experience, and efficacy of psilocybin for improving OCD, obtain the preliminary data needed as a pre-requisite to a larger-scale (efficacy or effectiveness) intervention study with dosing informed by this trial, and explore mechanism of anti-obsessional action.

03

Conditions studied

  • Obsessive - Compulsive Disorder

Keywords

  • obsessive compulsive disorder
  • OCD
  • psilocybin
  • psychedelic
  • psychedelic experiences
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years old, and older
  • Have OCD () based on diagnostic interview using the Structured Clinical Interview for DSM-5 Research Version (SCID).
  • At least moderate severity: Yale-Brown Obsessive-Compulsive Scale (YBOCS) score ≥16.
  • Failed at least one adequate trial of guideline concordant treatment.
  • Considered safe for independent living
  • Subjects must discontinue use of any of the following prescription or over the counter (OTC) products or nutritional supplements at least two weeks prior to initiating double-blind treatment:
  • Monoamine oxidase (MAOI), UGT1A10, and UGT1A9 inhibitors
  • Other active OCD treatments (cognitive behavioral therapy [CBT] or other psychotherapy; electrical or magnetic device treatments; pharmacological treatments such as antidepressant medications (e.g., SSRIs, SNRIs, MAOIs, TCAs, 5HT2 blockers, NERIs, etc.), lithium, antipsychotic drugs, 5-HT2 antagonists such as pimavanserin, and glutamatergic acting medications)

    • Note that fluoxetine must be discontinued at least 6 weeks prior to initiating double-blind treatment.
  • 5HT2 agonists (e.g., efavirenz, lorcaserin), which may alter the response to psilocybin
  • Serotonin-acting dietary supplements (e.g., 5-hydroxy-tryptophan, St. John's wort) due to potential for interaction with psilocybin and increased safety risks

Exclusion criteria

Exclusion Criteria:

  • Concurrent active substance use disorder, or a personal history of psychosis.
  • History of psychosis among first degree relatives as determined by the Family Interview for Genetic Studies (FIGS) 32
  • Medical illness based on physical examination and routine blood testing that may complicate cardiovascular safety or drug metabolism or excretion, such as uncontrolled hypertension, severe cardiac disease, or kidney or liver failure.
  • Unstable (COPD) or severe sleep apnea
  • renal or hepatic impairment, per clinical judgment of a study physician
  • ≥ 450 msec
  • Psychiatric comorbidity that may represent an acute risk to their own or other's safety.
  • Subjects cannot require any sedative, narcotic, or neuroleptic medications on a regular basis. Any of these medications they have taken should have been stopped long enough in the past to allow for their elimination and safe withdrawal prior to starting administration of the study drug. The specific time required will be dependent on the medication the patient was previously receiving.
  • Women who are pregnant, breastfeeding, or unwilling/unable to practice medically acceptable highly effective (double barrier, oral and injectable pharmacological contraceptives) during the study.
  • Suicidal behavior within the 12 months prior to enrollment, or significant risk of suicide as determined by the CSSRS items 4 (suicidal ideation with intent) and 5 (suicidal ideation with intent and plan) during screening or baseline assessment.
  • Any condition for which MRI is , at the discretion of a study investigator or the MRI technician, including: Pacemakers and defibrillators; artificial heart valves which are not MRI safe; any metal in head, spinal cord, eyes or chest; any electrical devices such as cochlear implants, nerve stimulators, deep brain stimulators, gastric pacemaker, or insulin or pain pumps; aneurysm clips; ferrous (i.e. non titanium alloy) implants in any part of the body.
  • Use within the week prior to screening of drugs of abuse as listed in the current US DOJ DEA Drugs of Abuse Resource Guide, including:
  • Cannabinoids (marijuana, synthetic cannabinoids)
  • Simulants (amphetamine, cocaine, methamphetamine, methylphenidate, modafinil)
  • Opioids (natural and synthetic),
  • Sedatives (benzodiazepines, barbiturates, GHB, zolpidem, zaleplon, zopiclone)
  • Hallucinogens (DMT, ibogaine, LSD, MDMA, psilocybin, psilocin, PSP)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Low Dose psilocybin (10mg)

    Subjects will receive a low dose (10mg) of psilocybin at four study drug ingesting sessions. Each drug ingestion session will be separated by three weeks.

    Drug: Low Dose Psilocybin

  • Active comparator
    High dose psilocybin (30mg)

    Subjects will receive a high dose (30mg) of psilocybin at four study drug ingesting sessions. Each drug ingestion session will be separated by three weeks.

    Drug: High Dose Psilocybin

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of orally administered psilocybin

    Determine the acute safety and tolerability of orally administered psilocybin at low dose (10mg) and high dose (30mg) as measured with the Systematic Assessment for Treatment Emergent Events (SAFTEE) scale.

    Time frame: 12 months

Secondary outcomes

  1. Efficacy of oral administered psilocybin in patient with OCD

    Determine the efficacy of two different doses (10mg and 30mg) of psilocybin as a treatment for OCD, and explore whether there may be a dose-response relationship. This will be based on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score.

    Time frame: 12 months

Other outcomes

  1. Impact of psilocybin administration in brain function

    Determine the impact of psilocybin administration in potential brain function OCD biomarkers

    Time frame: 12 months

07

Study locations

1 site
  • University of Arizona-Tucson
    Tucson, Arizona 85724, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Dec 2028, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
May 28, 2025
StartEst.
Sep 8, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06992999
Lead sponsor
Francisco A Moreno
Responsible party
Francisco A Moreno (Professor of Psychiatry, University of Arizona) — Sponsor-investigator
First posted
May 28, 2025
Start date
Sep 8, 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 12, 2026

Study contacts

Esmeralda Terrazas
Contact
esmeralda97h@arizona.edu
(520) 626-8000
Francisco Moreno, MD
principal investigator · University of Arizona, College of Medicine, Tucson

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion